葛兰素史克

最新新闻

• 评级变动
  Jefferies Maintains GlaxoSmithKline(GSK.US) With Buy Rating, Raises Target Price to $67.1
  \u5e02\u573a\u8d44\u8baf · 2026/5/29
• 评级变动
  J.P. Morgan Sticks to Its Sell Rating for GlaxoSmithKline (GSK)
  TipRanks · 2026/7/24
• 评级变动
  Jefferies Upgrades GlaxoSmithKline(GSK.US) to Buy Rating, Announces Target Price $55.6
  \u5e02\u573a\u8d44\u8baf · 2026/1/8
• 评级变动
  J.P. Morgan Reaffirms Their Sell Rating on GlaxoSmithKline (GSK)
  TipRanks · 2026/9/14
• 公司公告
  6-K: Gsk Enters Agreement to Acquire Idrx, Inc.
  SEC · 2025/1/13
• 公司公告
  6-K: Gsk Completes Acquisition of Idrx, Inc.
  SEC · 2025/2/24
• GSK Target Started at GBP19.75 by RBC
  Dow Jones · 2026/9/9
• 评级变动
  Barclays Initiates GlaxoSmithKline(GSK.US) With Sell Rating
  \u5e02\u573a\u8d44\u8baf · 2026/1/7
• GlaxoSmithKline (GSK) Gets a Sell From J.P. Morgan
  TipRanks · 2026/10/1
• 公司公告
  HENGRUI PHARMA: Inside Information Announcement and Overseas Regulatory Announcement - Entering into Collaboration, Option and License Agreement with GlaxoSmithKline Intellectual Property (No. 3) Limited and GlaxoSmithKline Intellectual Property (No. 4) Limited
  HKEX · 2025/7/28
• 评级变动
  J.P. Morgan Keeps Their Sell Rating on GlaxoSmithKline (GSK)
  TipRanks · 2026/9/1
• US Stock Market Movements | HUTCHMED (HCM.US) Surges Over 14% on Licensing Agreement with GlaxoSmithKline for Cancer Drug
  Zhitong Finance · 2026/9/3
• 评级变动
  GSK Target Raised to GBP22.00 From GBP20.00 by Berenberg
  Dow Jones · 2026/9/15
• 评级变动
  TD Cowen Maintains GlaxoSmithKline(GSK.US) With Hold Rating, Raises Target Price to $70
  \u5e02\u573a\u8d44\u8baf · 2026/2/9
• TD Cowen Upgrades GlaxoSmithKline(GSK.US) to Buy Rating, Maintains Target Price $70
  \u5e02\u573a\u8d44\u8baf · 2026/8/25
• J.P. Morgan Sticks to Their Sell Rating for GlaxoSmithKline (GSK)
  TipRanks · 2026/10/8
• 评级变动
  TD Cowen Maintains GlaxoSmithKline(GSK.US) With Hold Rating, Maintains Target Price $70
  \u5e02\u573a\u8d44\u8baf · 2026/8/3
• 公司公告
  6-K: Tesaro, A Gsk Subsidiary, Initiates Litigation Against Anaptysbio, Inc.
  SEC · 2025/11/21
• 评级变动
  J.P. Morgan Remains a Sell on GlaxoSmithKline (GSK)
  TipRanks · 2026/2/25
• 公司公告
  Beijing Wantai Biological Pharmacy Enterprise: Announcement from Beijing Wantai Biological Pharmacy Enterprise regarding the termination of the cooperation agreement with GSK by its wholly-owned subsidiary.
  SZSI · 2024/7/23
• 评级变动
  GlaxoSmithKline (GSK) Gets a Sell From J.P. Morgan
  TipRanks · 2026/7/17
• 评级变动
  J.P. Morgan Sticks to Their Sell Rating for GlaxoSmithKline (GSK)
  TipRanks · 2026/8/4
• GlaxoSmithKline (GSK.US) strengthens its oncology pipeline! Acquires trispecific T-cell engager from Enmabio for up to $750 million, targeting multiple myeloma.
  Zhitong Finance · 2026/9/15
• Hutchmed (00013.HK) announced that it has entered into a licensing agreement with GlaxoSmithKline for a KRAS-EGFR antibody-drug conjugate cancer therapy.
  Gelonghui Finance · 9/3

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。